Chris brings two decades of drug development experience in large pharma/biotech, with expertise in building and executing on strategies for both biomarker and bioanalytical development. An immunologist by training, Chris has deep knowledge in immunogenicity and has been one of the key drivers of the immunogenicity risk assessment framework widely utilized throughout the industry. Chris’s additional expertise in biomarker and bioanalytical assays covers a wide range of diseases areas and therapeutic modalities including protein therapeutics, antisense oligonucleotides and gene therapy. His drug development experience spans research through clinical development, including protocol development, study reporting, filings, and post marketing responses. Chris has an exceptional track record working with project teams to identify the critical questions/decision points and delivering strategies to address them, leading to efficient prosecution of their programs. He has a wide industry footprint, is an invited speaker at bioanalytical and biomarker focused meetings and has contributed to multiple industry white papers in the arena.